VaxNewMo LLC

Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors. Omniox adheres to NIH/PHS Financial Conflict of Interest requirements. Julia Simmons joined Omniox in 2018 and brings more than 25 years of experience in finance and accounting, including approximately 15 years in the biotherapeutics and medical device industries, from large publicly traded companies, such as Genentech, to small, privately-funded startup companies. Omniox is an IND-stage biotherapeutics company developing breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs. To pioneer innovative oxygen-based therapies that restore health to patients. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.

Omideon is focused on developing novel treatments for cancer by targeting the tumour glycome. Omideon’s lead candidate OMI-DG1, is a first-in-class multivalent CBM in development for ovarian cancer and colorectal cancer. Established in 2020, Omideon is a spin out from Pneumagen Limited. Prior to Omideon, Graeme headed up the oncology research and development division of Pneumagen for four years. Omideon is focused on developing carbohydrate binding modules (CBMs) as a new therapeutic modality to treat cancer and target Tumour Associated Carbohydrate Antigens (TACAs). Omideon’s lead candidate, OMI-DG1, is a first-in-class multivalent CBM (mCBM) in development for the treatment of ovarian cancer and colorectal cancer. Omideon has successfully raised investment to expand the indication of OMI-DG1 for colorectal cancer. Graeme is an inventor of Omideon’s intellectual property and helped found Omideon.

Join us in our mission:Healthcare for everyone, everywhere. Omniscope welcomes collaborations with innovators in the areas of oncology, infectious diseases, and autoimmune diseases.Start seeing what our immune system is seeing. Omniscope is a techbio company decoding the immune system. A mission-driven technology to put science in service of humanity. Holger is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative. Romain is a commercial executive with a passion for healthcare.

Since 2021 Gnubiotics has been developing a next generation of immunotherapy and now seeks to progress its lead candidate, GNU101, a promising glycopeptide therapeutic to the next step of IND approval and phase 1 trials. Gnubiotics Sciences SA is partnering with top-tier academic medical centers to move into first clinical trials. We are impacting 4 areas of high unmet needthrough the GENESIS platform:. The glycopeptides developed by Gnubiotics have been demonstrated to intelligently promote microbiome balance by specifically promoting the growth of beneficial bacteria. Glyopeptide variants developed by Gnubiotics have been demonstrated to reduce the onset of diet induced obesity and enhance thermogenesis through a number of hypothesized mechanisms of action. Gnubiotics is interested in further investigating this promising MoAs through partnerships and collaborations. Prior to co-founding Gnubiotics, Bernardo worked as an investment banker and had an impact as a consultant. We have mastered the intelligent, rational design and manufacturing of precise complex glycopeptide biologics that target and affect these biological systems.

Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell immune responses generated by its proprietary oligoDOM® technology, and B-cell responses brought by conventional vaccines. Osivax’ mission is to develop universal vaccine candidates designed to provide protection against viruses that mutate rapidly, starting with influenza and rapidly expanding to other areas such as sarbecovirus, HPV…. Founded in 2017, Osivax’ management team consists of experienced multi-disciplinary professionals committed to executing on the platform’s potential and who are supported by premier scientific and clinical advisory boards. Since 2017, Osivax’ team has developed its universal influenza vaccine from preclinical stage to phase 2 trials with over 1,200 subjects recruited so far and several proofs of concept generated on the platform technology. Osivax is based in Lyon, France and Liège, Belgium, two of the premier vaccine R&D clusters in Europe. Osivax recently incorporated an affiliate in Australia to oversee local clinical trials. Osivax’ approach and mission are further validated and supported by our trusted investors. Osivax is leveraging its oligoDOM® self-assembling nanoparticles platform technology to develop universal vaccines against constantly mutating pathogens.

Omnio AB is a biopharmaceutical company specializing in the development of new drug products based on the pro-inflammatory and immunoregulatory effects of the protein plasminogen. Omnio focuses on developing recombinant plasminogen for chronic wound healing, where initial physician-led studies of patients with chronic wounds have shown great potential. We develop disruptive treatments that improve lives while lowering the overall cost of health care with plasminogen-based therapeutics. Omnio is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations. Omnio is developing recombinant plasminogen for treatment of chronic wounds. Our ambition is to change today's wound healing treatment and provide an effective alternative to patients where effective bioactive treatment is lacking. Unlike other products available on the market, plasminogen has been shown to be a key regulatory molecule that activates all stages of the wound healing process. We focus on delivering transformative treatment for chronic wounds and where there is little to no pharmacologically active treatment available today.